During a live event, Nathan Denlinger, DO, MS, discussed bridging therapy and patient barriers to CAR T-cell therapy.

Jacob Sands, MD, discusses the data that support the FDA accelerated approval of Dato-DXd in EGFR-positive non–small cell ...

Early data from the DURIPANC study shows promising safety and survival benefits of rintatolimod and durvalumab for metastatic ...

Pirtobrutinib shows promising results in treating CLL, outperforming ibrutinib in a pivotal phase 3 trial, paving the way for ...

New long-term data highlights the effectiveness and safety of ivosidenib with azacitidine for treating IDH1-mutated AML, ...

FDA grants fast track designation to CLD-201, an innovative therapy for soft tissue sarcoma, enhancing its development and ...

An expert discusses how the ZUMA-7 trial marked a pivotal shift in the treatment of primary refractory diffuse large B-cell lymphoma by demonstrating that second-line CAR T-cell therapy not only ...

The oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX A51 revealed a manageable safety profile in relapsed ...

An expert discusses that while the liso-cel trial did not show a statistically significant overall survival benefit—likely ...

An expert discusses the multifaceted nature of CAR T-cell therapy for relapsed/refractory (R/R) large B-cell lymphoma (LBCL), ...

Panelists discuss how the treatment landscape for treatment-naive patients with chronic lymphocytic leukemia (CLL) is rapidly ...

Panelists discuss how the updated SEQUOIA Arm C data demonstrate that zanubrutinib monotherapy achieves a remarkable 72% ...